Sesen Bio Inc. [NASDAQ: SESN] price surged by 20.26 percent to reach at $0.11. The company report on May 9, 2022 that Sesen Bio Reports First Quarter 2022 Financial Results and Business Update.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Strong balance sheet of $170 million in cash and cash equivalents as of March 31, 2022, expected to fund current operating plan into the fourth quarter of 2024.
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the first quarter ended March 31, 2022. During the quarter, the Company continued to engage with the US Food and Drug Administration (FDA) to identify an anticipated regulatory path toward potential resubmission of a Biologics License Application (BLA) for Vicineum™ for the treatment of non-muscle invasive bladder cancer (NMIBC). The Company has also initiated a process to review strategic alternatives with the goal of maximizing shareholder value.
A sum of 11533980 shares traded at recent session while its average daily volume was at 4.07M shares. Sesen Bio Inc. shares reached a high of $0.696 and dropped to a low of $0.5677 until finishing in the latest session at $0.68.
The one-year SESN stock forecast points to a potential upside of 61.8. The average equity rating for SESN stock is currently 2.30, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Sesen Bio Inc. [SESN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SESN shares is $1.78 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SESN stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Sesen Bio Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on August 16, 2021. The new note on the price target was released on June 11, 2019, representing the official price target for Sesen Bio Inc. stock.
The Average True Range (ATR) for Sesen Bio Inc. is set at 0.07, with the Price to Sales ratio for SESN stock in the period of the last 12 months amounting to 6.35. The Price to Book ratio for the last quarter was 0.78, with the Price to Cash per share for the same quarter was set at 0.82.
SESN Stock Performance Analysis:
Sesen Bio Inc. [SESN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 29.87. With this latest performance, SESN shares gained by 18.01% in over the last four-week period, additionally sinking by -25.28% over the last 6 months – not to mention a drop of -82.78% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SESN stock in for the last two-week period is set at 67.93, with the RSI for the last a single of trading hit 74.08, and the three-weeks RSI is set at 62.92 for Sesen Bio Inc. [SESN]. The present Moving Average for the last 50 days of trading for this stock 0.5200, while it was recorded at 0.6067 for the last single week of trading, and 0.7873 for the last 200 days.
Insight into Sesen Bio Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Sesen Bio Inc. [SESN] shares currently have an operating margin of -106.09 and a Gross Margin at +99.68. Sesen Bio Inc.’s Net Margin is presently recorded at -1.27.
Return on Equity for this stock declined to -0.41, with Return on Assets sitting at -0.13.
Sesen Bio Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 21.30 and a Current Ratio set at 21.30.
Sesen Bio Inc. [SESN] Insider Position Details
There are presently around $28 million, or 22.60% of SESN stock, in the hands of institutional investors. The top three institutional holders of SESN stocks are: BLACKROCK INC. with ownership of 13,387,891, which is approximately -0.747% of the company’s market cap and around 0.90% of the total institutional ownership; VANGUARD GROUP INC, holding 12,694,776 shares of the stock with an approximate value of $7.2 million in SESN stocks shares; and STATE STREET CORP, currently with $2.46 million in SESN stock with ownership of nearly 1.219% of the company’s market capitalization.
Positions in Sesen Bio Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 26 institutional holders increased their position in Sesen Bio Inc. [NASDAQ:SESN] by around 2,285,593 shares. Additionally, 47 investors decreased positions by around 6,002,166 shares, while 32 investors held positions by with 40,588,942 shares. The mentioned changes placed institutional holdings at 48,876,701 shares, according to the latest SEC report filing. SESN stock had 9 new institutional investments in for a total of 1,659,396 shares, while 17 institutional investors sold positions of 1,785,256 shares during the same period.